MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.040
+0.160
+5.56%
After Hours: 3.040 0 0.00% 17:37 05/17 EDT
OPEN
2.870
PREV CLOSE
2.880
HIGH
3.150
LOW
2.860
VOLUME
32.19K
TURNOVER
--
52 WEEK HIGH
14.43
52 WEEK LOW
2.720
MARKET CAP
67.40M
P/E (TTM)
-1.6712
1D
5D
1M
3M
1Y
5Y
BRIEF-Neurobo Pharmaceuticals Posts Q1 Loss Per Share Of $0.15
reuters.com · 1h ago
NeuroBo Pharmaceuticals EPS beats by $0.01
NeuroBo Pharmaceuticals (NRBO): Q1 GAAP EPS of -$0.15 beats by $0.01.Cash and Cash Equivalents were $13MPress Release
Seekingalpha · 1h ago
NeuroBo Pharmaceuticals Q1 EPS $(0.15) Up From $(0.30) YoY
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.15) per share. This is a 50 percent increase over losses of $(0.30) per share from the same period last year.
Benzinga · 1h ago
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results
, /PRNewswire/ --(Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the first...
PR Newswire - PRF · 1h ago
BRIEF-Neurobo Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
reuters.com · 3d ago
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 3d ago
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 6d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 05/07 11:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRBO. Analyze the recent business situations of NeuroBo Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NRBO stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 4.12M
% Owned: 18.56%
Shares Outstanding: 22.17M
TypeInstitutionsShares
Increased
6
678.07K
New
1
19.18K
Decreased
5
6.75K
Sold Out
2
33.16K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
Jeong Gu Kang
Chairman/Director
Douglas Swirsky
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
jeong Gu Kang
Chief Operating Officer/Senior Vice President/Director
Akash Bakshi
Senior Vice President
Andrew Bartynski
Senior Vice President
Nadja Mannowetz
Other
Mark Versavel
Independent Director
Jason Groves
Independent Director
Jeong Gyun Oh
Independent Director
Michael Salsbury
No Data
About NRBO
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.